Entering text into the input field will update the search result below

Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q4 2020 Results - Earnings Call Transcript

Mar. 09, 2021 8:50 PM ETLyra Therapeutics, Inc. (LYRA) Stock
SA Transcripts profile picture
SA Transcripts

Lyra Therapeutics, Inc. (NASDAQ:LYRA) Q4 2020 Earnings Conference Call March 9, 2021 4:30 PM ET

Company Participants

Laurence Watts - Managing Director, Gilmartin Group

Maria Palasis - President & Chief Executive Officer

Rob Kern - Chief Medical Officer

Don Elsey - Chief Financial Officer

Corinne Noyes - Senior Vice President of Commercial Strategy & Market Development

Conference Call Participants

Chris Howerton - Jefferies

Bert Hazlett - BTIG

Ash Verma - Bank of America

Tim Lugo - William Blair


Welcome to the Lyra Therapeutics Fourth Quarter and End Year 2020 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Following management's prepare remarks, we will hold a Q&A session. [Operator Instructions] As a reminder, this call is being recorded today March 9, 2021.

I would now like to turn the conference call over to Laurence Watts, Managing Director at Gilmartin Group. Please, go ahead.

Laurence Watts

Thank you, Terry. Joining us on the call today from Lyra Therapeutics are President and Chief Executive Officer, Maria Palasis; Chief Financial Officer, Don Elsey; Chief Medical Officer, Rob Kern; and Senior Vice President of Commercial Strategy and Market Development, Corinne Noyes.

Early today, Lyra released financial results for the fourth quarter ended December 31, 2020. If you have not received this news release, or you -- to be added to the company's distribution list to receive future releases, please go to the investor relations section of Lyra's website, which can be found at www.lyratherapeutics.com.

During the conference call management will make forward-looking statements, including statements related to Lyra's financial results and guidance for 2021, and the clinical development of the company's product candidates, business strategy and planned operations. These forward-looking statements are based on the company's current expectations and inherently involves significant risks and uncertainties. Lyra's actual results and the

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About LYRA

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on LYRA

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.